Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 2
2006 4
2007 3
2008 6
2009 7
2010 4
2011 9
2012 14
2013 20
2014 13
2015 14
2016 17
2017 25
2018 24
2019 29
2020 44
2021 32
2022 27
2023 37
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

291 results

Results by year

Filters applied: . Clear all
Page 1
Teduglutide.
[No authors listed] [No authors listed] 2023 Sep 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Sep 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 36701512 Free Books & Documents. Review.
Because it is a large protein molecule with a molecular weight of 3752 Da, the amount in milk is likely to be very low. Teduglutide is also poorly absorbed orally so absorption by a breastfed infant is unlikely. Two breastfed infants apparently experienced no adverse effec …
Because it is a large protein molecule with a molecular weight of 3752 Da, the amount in milk is likely to be very low. Teduglutide i …
Teduglutide for pediatric short bowel syndrome patients.
Rosete BE, Wendel D, Horslen SP. Rosete BE, et al. Expert Rev Gastroenterol Hepatol. 2021 Jul;15(7):727-733. doi: 10.1080/17474124.2021.1913052. Epub 2021 Apr 26. Expert Rev Gastroenterol Hepatol. 2021. PMID: 33798402 Review.
Areas covered: This article reviews the pharmacology, safety, efficacy, and tolerability of GLP-2 analog teduglutide in pediatric patients greater than 1 year of age. We review all current studies and discuss teduglutide's place in pediatric SBS therapy. Expert opin …
Areas covered: This article reviews the pharmacology, safety, efficacy, and tolerability of GLP-2 analog teduglutide in pediatric pat …
Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure.
Jeppesen PB, Pertkiewicz M, Messing B, Iyer K, Seidner DL, O'keefe SJ, Forbes A, Heinze H, Joelsson B. Jeppesen PB, et al. Gastroenterology. 2012 Dec;143(6):1473-1481.e3. doi: 10.1053/j.gastro.2012.09.007. Epub 2012 Sep 11. Gastroenterology. 2012. PMID: 22982184 Clinical Trial.
Teduglutide increased plasma concentrations of citrulline, a biomarker of mucosal mass. The distribution of treatment-emergent adverse events that led to study discontinuation was similar between patients given teduglutide (n = 2) and placebo (n = 3). CONCLUSIONS: T …
Teduglutide increased plasma concentrations of citrulline, a biomarker of mucosal mass. The distribution of treatment-emergent advers …
Teduglutide for short bowel syndrome.
[No authors listed] [No authors listed] Aust Prescr. 2020 Apr;43(2):72-73. doi: 10.18773/austprescr.2020.017. Epub 2020 Mar 3. Aust Prescr. 2020. PMID: 32346219 Free PMC article. Review. No abstract available.
Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24-Week, Phase III Study.
Kocoshis SA, Merritt RJ, Hill S, Protheroe S, Carter BA, Horslen S, Hu S, Kaufman SS, Mercer DF, Pakarinen MP, Venick RS, Wales PW, Grimm AA. Kocoshis SA, et al. JPEN J Parenter Enteral Nutr. 2020 May;44(4):621-631. doi: 10.1002/jpen.1690. Epub 2019 Sep 8. JPEN J Parenter Enteral Nutr. 2020. PMID: 31495952 Free PMC article.

The primary end point was achieved by 13 (54.2%), 18 (69.2%), and 1 (11.1%) patients who received 0.025 mg/kg teduglutide, 0.05 mg/kg teduglutide, and SOC, respectively (P < 0.05 vs SOC). ...Two (8.3%, 0.025 mg/kg teduglutide) and 3 patients (11.5%, 0.05 m

…
The primary end point was achieved by 13 (54.2%), 18 (69.2%), and 1 (11.1%) patients who received 0.025 mg/kg teduglutide, 0.05 mg/kg …
Efficacy of Teduglutide for Parenteral Support Reduction in Patients with Short Bowel Syndrome: A Systematic Review and Meta-Analysis.
Bioletto F, D'Eusebio C, Merlo FD, Aimasso U, Ossola M, Pellegrini M, Ponzo V, Chiarotto A, De Francesco A, Ghigo E, Bo S. Bioletto F, et al. Nutrients. 2022 Feb 14;14(4):796. doi: 10.3390/nu14040796. Nutrients. 2022. PMID: 35215445 Free PMC article. Review.
Teduglutide has been described as an effective treatment for parenteral support (PS) reduction in patients with short bowel syndrome (SBS). ...This was the first meta-analysis that specifically assessed the efficacy of teduglutide in adult patients with SBS. Our res …
Teduglutide has been described as an effective treatment for parenteral support (PS) reduction in patients with short bowel syndrome …
Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support.
Chiba M, Masumoto K, Kaji T, Matsuura T, Morii M, Fagbemi A, Hill S, Pakarinen MP, Protheroe S, Urs A, Chen ST, Sakui S, Udagawa E, Wada M. Chiba M, et al. J Pediatr Gastroenterol Nutr. 2023 Sep 1;77(3):339-346. doi: 10.1097/MPG.0000000000003867. Epub 2023 Jun 26. J Pediatr Gastroenterol Nutr. 2023. PMID: 37364133 Free PMC article. Clinical Trial.
All adverse events (AEs) were in line with known impacts of SBS-IF and adverse reactions to teduglutide. Only one serious AE (abdominal pain) was considered related to teduglutide. ...Teduglutide was well tolerated, and efficacy improved with longer-term trea …
All adverse events (AEs) were in line with known impacts of SBS-IF and adverse reactions to teduglutide. Only one serious AE (abdomin …
Teduglutide: A Review in Short Bowel Syndrome.
Kim ES, Keam SJ. Kim ES, et al. Drugs. 2017 Mar;77(3):345-352. doi: 10.1007/s40265-017-0703-7. Drugs. 2017. PMID: 28194723 Review.
Subcutaneous teduglutide (Revestive()), a glucagon-like peptide-2 analogue that increases intestinal absorption, is approved in the EU for the treatment of short bowel syndrome (SBS) in patients aged 1 year who are stable following a period of postsurgical intestinal adapt …
Subcutaneous teduglutide (Revestive()), a glucagon-like peptide-2 analogue that increases intestinal absorption, is approved in the E …
Teduglutide for the Treatment of Short Bowel Syndrome.
Wilhelm SM, Lipari M, Kulik JK, Kale-Pradhan PB. Wilhelm SM, et al. Ann Pharmacother. 2014 Sep;48(9):1209-1213. doi: 10.1177/1060028014537468. Epub 2014 May 28. Ann Pharmacother. 2014. PMID: 24871569 Review.
The methods and results from each of the trials were extracted. DATA SYNTHESIS: Teduglutide has been studied in SBS in 3 phase III trials. Teduglutide decreases parenteral nutrition (PN) volume requirements, with 1 study showing a reduction of 4.4 3.8 L/wk with t …
The methods and results from each of the trials were extracted. DATA SYNTHESIS: Teduglutide has been studied in SBS in 3 phase III tr …
Teduglutide for treatment of adult patients with short bowel syndrome.
Billiauws L, Bataille J, Boehm V, Corcos O, Joly F. Billiauws L, et al. Expert Opin Biol Ther. 2017 May;17(5):623-632. doi: 10.1080/14712598.2017.1304912. Expert Opin Biol Ther. 2017. PMID: 28293969 Review.
The aim of treatment is to maximize intestinal absorption and reduce or eliminate the need for HPS to achieve the best possible quality of life. Teduglutide, an analog of glucagon-like peptide 2, improves intestinal rehabilitation by promoting mucosal growth, reducing inte …
The aim of treatment is to maximize intestinal absorption and reduce or eliminate the need for HPS to achieve the best possible quality of l …
291 results